Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.165 EUR | -0.86% | +1.66% | +33.59% |
07/05 | AstraZeneca target raised; Antofagasta lowered | AN |
03/05 | AIB GROUP : Stronger revenue growth and a benign cost of risk |
Sales 2024 * | 455.65Cr 494.11Cr 41TCr | Sales 2025 * | 434.04Cr 470.68Cr 39TCr | Capitalization | 1.25TCr 1.35TCr 1,12800Cr |
---|---|---|---|---|---|
Net income 2024 * | 176.2Cr 191.07Cr 16TCr | Net income 2025 * | 156.1Cr 169.28Cr 14TCr | EV / Sales 2024 * | 2.74 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.87 x |
P/E ratio 2024 * |
7.19
x | P/E ratio 2025 * |
7.48
x | Employees | - |
Yield 2024 * |
5.83% | Yield 2025 * |
6.18% | Free-Float | 68.01% |
Latest transcript on AIB Group plc
1 week | +1.66% | ||
Current month | +5.17% | ||
1 month | +8.00% | ||
3 months | +18.95% | ||
6 months | +23.69% | ||
Current year | +33.59% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 01/16/01 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 01/13/01 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 19/23/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fergal O’Dwyer
BRD | Director/Board Member | 64 | 22/21/22 |
James Pettigrew
CHM | Chairman | 65 | 28/21/28 |
Brendan McDonagh
BRD | Director/Board Member | 66 | 27/16/27 |
Date | Price | Change |
---|---|---|
29/24/29 | 5.165 | -0.86% |
28/24/28 | 5.21 | +1.36% |
27/24/27 | 5.14 | -3.11% |
24/24/24 | 5.305 | +0.86% |
23/24/23 | 5.26 | +0.86% |
Real-time BOERSE MUENCHEN, May 29, 2024 at 04:13 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.28% | 57TCr | |
+16.78% | 31TCr | |
+19.11% | 26TCr | |
+20.85% | 21TCr | |
+22.37% | 19TCr | |
+26.85% | 17TCr | |
+7.69% | 16TCr | |
+6.95% | 15TCr | |
-11.76% | 14TCr |
- Stock Market
- Equities
- A5G Stock
- A5G Stock